UCLA Campus    |   UCLA Health    |   School of Medicine Translate:
UCLA Health It Begins With U

Hepatitis Co-Infection Studies

The UCLA CARE Center has studies currently enrolling to examine if new hepatitis C drugs, boceprevir and telaprevir, can be used in combination with 2 other hepatitis C drugs, pegylated interferon and ribavirin, to treat hepatitis C virus (HCV) in participants with both HCV and HIV.  These studies are open to participants who have already taken medications for HCV and to those who have never taking medications for HCV.

ACTG 5294

Study for men and women who have both HIV and Hepatitis C (HCV) infection and have either never received HCV treatment before or did not respond to prior treatment. Only those with genotype 1 HCV may participate. This study examines if adding a third drug, boceprevir, to the standard treatment of pegylated interferon and ribavirin is safe and works in those with both HIV and HCV.

Viral Hepatitis Registry

If you are interested in participating in research studies on viral Hepatitis B or Hepatitis C, either now or at a future date, you can join our contact list to be informed of upcoming research that may match your needs.

Hepatitis FAQ

What is Hepatitis C?

Hepatitis C is a contagious liver disease that results from infection with the Hepatitis C virus (HCV). It can range in severity from a mild illness lasting a few weeks to a serious, lifelong illness. Hepatitis C is usually spread when blood from a person infected with HCV enters the body of someone who is not infected. Today, most people become infected with HCV by sharing needles or other equipment to inject drugs.

Hepatitis C can be either "acute" or "chronic." Acute Hepatitis C virus infection is a short-term illness that occurs within the first 6 months after someone is exposed to HCV. For most people, acute infection leads to chronic infection. Chronic Hepatitis C is a serious disease than can result in long-term health problems, or even death.

There are several strains (types) of hepatitis C found in the United States which are known as genotypes.  Different medications have been shown to be effective in decreasing the amount of HCV in the blood, which can help to reduce liver damage from HCV.

What about Hepatitis C and HIV Co-Infection?

About one quarter of HIV-infected persons in the United States are also infected with HCV.  HCV is one of the most important causes of chronic liver disease in the United States and HCV infection progresses more rapidly to liver damage in HIV-infected persons. HCV infection may also impact the course and management of HIV infection.

The UCLA CARE Center is conducting research studies for participants either mono-infected only with HCV or co-infected with HCV and HIV.  These studies test to see if new drugs are helpful in reducing the amount of HCV in the blood, as well as to see how much medicine is needed to be most effective in reducing HCV.

How can I learn more?

For more information about the UCLA CARE Center and our research on HCV and HIV/HCV, or to find out if you qualify for any of our studies, please contact us:
Phone:  (310) 557-9062
Email:  CAREoutreach@mednet.ucla.edu